BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26756583)

  • 1. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
    Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
    Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma.
    Görögh T; Weise JB; Holtmeier C; Rudolph P; Hedderich J; Gottschlich S; Hoffmann M; Ambrosch P; Csiszar K
    J Pathol; 2007 May; 212(1):74-82. PubMed ID: 17354256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of the 5' flanking domain of the LOXL4 gene in head and neck squamous cell carcinoma cells.
    Görögh T; Holtmeier C; Weise JB; Hoffmann M; Ambrosch P; Laudien M; Csiszar K
    Int J Oncol; 2008 Nov; 33(5):1091-8. PubMed ID: 18949373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
    Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
    Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma.
    Scola N; Görögh T
    Anticancer Res; 2010 Nov; 30(11):4567-71. PubMed ID: 21115907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head and neck cancer cells and xenografts are very sensitive to palytoxin: decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity.
    Görögh T; Bèress L; Quabius ES; Ambrosch P; Hoffmann M
    Mol Cancer; 2013 Feb; 12():12. PubMed ID: 23409748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of 131I-labeled anti-CK8 monoclonal antibody in HNSCC in xenotransplanted SCID mice.
    Andratschke M; Luebbers CW; Johannson V; Schmitt B; Mack B; Zeidler R; Lang S; Wollenberg B; Gildehaus FJ
    Anticancer Res; 2011 Oct; 31(10):3315-21. PubMed ID: 21965741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
    Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
    Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
    Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
    Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
    Finkel KA; Warner KA; Kerk S; Bradford CR; McLean SA; Prince ME; Zhong H; Hurt EM; Hollingsworth RE; Wicha MS; Tice DA; Nör JE
    Neoplasia; 2016 May; 18(5):273-281. PubMed ID: 27237319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer.
    Weise JB; Csiszar K; Gottschlich S; Hoffmann M; Schmidt A; Weingartz U; Adamzik I; Heiser A; Kabelitz D; Ambrosch P; Görögh T
    Int J Oncol; 2008 Feb; 32(2):317-22. PubMed ID: 18202753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer.
    Weise JB; Rudolph P; Heiser A; Kruse ML; Hedderich J; Cordes C; Hoffmann M; Brant O; Ambrosch P; Csiszar K; Görögh T
    Eur J Cancer; 2008 Jun; 44(9):1323-31. PubMed ID: 18499440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas.
    Holtmeier C; Görögh T; Beier U; Meyer J; Hoffmann M; Gottschlich S; Heidorn K; Ambrosch P; Maune S
    Anticancer Res; 2003; 23(3B):2585-91. PubMed ID: 12894545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.